Inflammatory and Toxic Myopathy

Abstract

Although muscle diseases are relatively rare, several treatable myopathies must be recognized by the clinician to maximize the possibility of restoring strength in affected patients. The inflammatory myopathies, including polymyositis, dermatomyositis, inflammatory necrotizing myopathy, and myositis in association with mixed connective tissue disease, typically respond well to immunosuppressive treatment. Inclusion body myositis, a myopathy that has features of both inflammation and primary degeneration, may not be treatable at this time, but treatments are actively being sought. Muscle dysfunction caused by toxins must also be recognized because removal of the offending toxin usually results in restoration of normal muscle function. Important muscle toxins include cholesterol-lowering medications, colchicine, zidovudine, corticosteroids, emetine, and ethanol.

Keywords

myositis - polymyositis - dermatomyositis - inclusion body myositis - necrotizing myopathy - toxic myopathy - cholesterol-lowering agent myopathy

• Reference

• 1 Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009; 80 (10) 1060-1068
• 2 Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15 (3) 168-178
• 3 Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56 (4) 255-286
• 4 Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 2009; 80 (8) 904-908
• 5 Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16 (6) 692-699
• 6 Hengstman GJ, ter Laak HJ, Vree Egberts WT , et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65 (12) 1635-1638
• 7 Rutkove SB, De Girolami U, Preston DC , et al. Myotonia in colchicine myoneuropathy. Muscle Nerve 1996; 19 (7) 870-875
• 8 Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996; 46 (3) 731-736
• 9 Rich MM, Pinter MJ, Kraner SD, Barchi RL. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998; 43 (2) 171-179
• 10 Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16 (2) 193-208
• 11 Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16 (2) 209-215
• 12 Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80 (11) 1186-1193
• 13 Bronner IM, Hoogendijk JE, Wintzen AR , et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003; 250 (4) 480-485
• 14 Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41 (6) 936-939
• 15 Callen JP. Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis. Rheum Dis Clin North Am 1994; 20 (4) 943-953
• 16 Joffe MM, Love LA, Leff RL , et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94 (4) 379-387
• 17 Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 1986; 36 (1) 35-39
• 18 Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44 (3) 386-389
• 19 Goei The HS, Jacobs P, Houben H. Cyclosporine in the treatment of intractable polymyositis. Arthritis Rheum 1985; 28 (12) 1436-1437
• 20 Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353 (9166) 1762-1763
• 21 Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989; 16 (9) 1225-1228
• 22 Fries JF, Sharp GC, McDevitt HO, Holman HR. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum 1973; 16 (2) 154-162
• 23 Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36 (3) 319-324
• 24 Dalakas MC, Illa I, Dambrosia JM , et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329 (27) 1993-2000
• 25 Hennekens CH. Statin-induced myopathy: hypothesis about randomized evidence and clinical impressions. Am J Med 2009; 122 (1) 4-5
• 26 McAdams M, Staffa J, Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2008; 17 (3) 229-239
• 27 Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008; 20 (6) 648-655
• 28 Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41 (2) 185-190
• 29 Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin 2005; 23 (2) 397-428
• 30 Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316 (25) 1562-1568
• 31 Kuncl RW, Cornblath DR, Avila O, Duncan G. Electrodiagnosis of human colchicine myoneuropathy. Muscle Nerve 1989; 12 (5) 360-364
• 32 Kiyomoto BH, Tengan CH, Godinho RO. Effects of short-term zidovudine exposure on mitochondrial DNA content and succinate dehydrogenase activity of rat skeletal muscle cells. J Neurol Sci 2008; 268 (1-2) 33-39
• 33 Mhiri C, Baudrimont M, Bonne G , et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991; 29 (6) 606-614
• 34 Pascuzzi RM. Drugs and toxins associated with myopathies. Curr Opin Rheumatol 1998; 10 (6) 511-520
• 35 Kissel JT, Mendell JR. The endocrine myopathies. In: Rowland LP, DiMauro S, , eds. Handbook of Clinical Neurology. Amsterdam: Elsevier; 1992: 527-551
• 36 Faludi G, Gotlieb J, Meyers J. Factors influencing the development of steroid-induced myopathies. Ann N Y Acad Sci 1966; 138 (1) 62-72
• 37 Hirano M, Ott BR, Raps EC , et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992; 42 (11) 2082-2087
• 38 MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet 1977; 2 (8038) 615
• 39 Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 1998; 21 (5) 610-617
• 40 Palmer EP, Guay AT. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders. N Engl J Med 1985; 313 (23) 1457-1459
• 41 Amato AA, Kagan-Hallet K, Jackson CE , et al. The wide spectrum of myofibrillar myopathy suggests a multifactorial etiology and pathogenesis. Neurology 1998; 51 (6) 1646-1655